Dietary Intake by Patients Taking GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Narrative Review and Discussion of Research Needs

Glucagon-like peptide receptor agonists (GLP-1RAs) and dual mechanism glucose-dependent insulinotropic polypeptide/glucagon-like peptide receptor agonists (GIP/GLP-1RAs) are effective treatments for weight loss and diabetes management. They reduce appetite and caloric intake by 16–39%. However, studies provide limited data on their impact on diet composition, eating patterns, and macronutrient or micronutrient intake. This video explores key findings from a narrative review, highlighting what we know—and don’t know—about dietary changes during GLP-1 therapy. It also uncovers critical gaps in research and discusses why understanding these changes is essential for improving patient outcomes.

The original article, "Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs," was published in Obesity Pillars in July 2024.

Christensen S, Robinson K, Thomas S, Williams DR. Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs. Obes Pillars. 2024 Jul 25;11:100121. doi: 10.1016/j.obpill.2024.100121. Erratum in: Obes Pillars. 2024 Oct 02;12:100136. doi: 10.1016/j.obpill.2024.100136.